NASDAQ:ACON Aclarion (ACON) Stock Price, News & Analysis $3.50 +0.00 (+0.06%) Closing price 03:58 PM EasternExtended Trading$3.37 -0.13 (-3.77%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Aclarion Stock (NASDAQ:ACON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aclarion alerts:Sign Up Key Stats Today's Range$3.38▼$3.4950-Day Range$3.06▼$3.7352-Week Range$2.34▼$12.03Volume55,527 shsAverage Volume81,990 shsMarket Capitalization$8.61 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingHold Company Overview Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. Read More Aclarion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreACON MarketRank™: Aclarion scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingAclarion has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAclarion has a consensus price target of $7.50, representing about 114.2% upside from its current price of $3.50.Amount of Analyst CoverageAclarion has only been the subject of 2 research reports in the past 90 days.Read more about Aclarion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclarion is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclarion is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclarion has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aclarion's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.13% of the float of Aclarion has been sold short.Short Interest Ratio / Days to CoverAclarion has a short interest ratio ("days to cover") of 4.02.Change versus previous monthShort interest in Aclarion has recently decreased by 24.50%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAclarion does not currently pay a dividend.Dividend GrowthAclarion does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.99 News SentimentAclarion has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Aclarion this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ACON on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Aclarion in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $50,915.00 in company stock, which represents 0.5905% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Aclarion insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,915.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.01% of the stock of Aclarion is held by insiders.Percentage Held by Institutions7.52% of the stock of Aclarion is held by institutions.Read more about Aclarion's insider trading history. Receive ACON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACON Stock News HeadlinesAclarion Expands Nociscan Availability in Greater Los Angeles Through Partnership with Institute of Neuro InnovationJune 3 at 6:31 AM | quiverquant.comQAclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence GenerationJune 3 at 6:00 AM | globenewswire.comYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.June 3 at 1:00 AM | Profits Run (Ad)Aclarion's Nociscan Technology Linked to Immune Signatures in Back Pain Study, Expanding Clinical ApplicationsJune 1 at 6:31 AM | quiverquant.comQAclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker StudyJune 1 at 6:00 AM | globenewswire.comAclarion (NASDAQ:ACON) Given New $7.50 Price Target at Ascendiant Capital MarketsMay 30, 2026 | americanbankingnews.comInsider Buying: Aclarion (NASDAQ:ACON) Director Buys 5,664 Shares of StockMay 13, 2026 | insidertrades.comAclarion (NASDAQ:ACON) CEO Brent Ness Acquires 6,289 SharesMay 12, 2026 | insidertrades.comSee More Headlines ACON Stock Analysis - Frequently Asked Questions How have ACON shares performed this year? Aclarion's stock was trading at $4.60 at the beginning of the year. Since then, ACON shares have decreased by 23.9% and is now trading at $3.5020. How were Aclarion's earnings last quarter? Aclarion, Inc. (NASDAQ:ACON) posted its quarterly earnings data on Wednesday, May, 13th. The company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.55) by $0.21. The company earned $0.02 million during the quarter, compared to analyst estimates of $0.03 million. Aclarion had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 10,320.51%. When did Aclarion's stock split? Shares of Aclarion reverse split on the morning of Friday, March 28th 2025.The 1-27 reverse split was announced on Wednesday, March 26th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How will Aclarion's stock buyback program work? Aclarion's Board of Directors approved a stock repurchase program on Wednesday, April 22nd 2026, which allows the company to buy back $2,500,000 in shares, according to EventVestor. This means that the company could reacquire up to 31% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued. When did Aclarion IPO? Aclarion (ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share. How do I buy shares of Aclarion? Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aclarion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aclarion investors own include Broadcom (AVGO), Meta Platforms (META), Norwegian Cruise Line (NCLH), Audioeye (AEYE), Advanced Micro Devices (AMD), ASML (ASML) and AvidXchange (AVDX). Company Calendar Last Earnings5/13/2026Today6/03/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (27m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ACON's financial health is in the Red zone, according to TradeSmith. ACON has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryHealthcare Current SymbolNASDAQ:ACON CIK1635077 Webwww.aclarion.com Phone833-275-2266FaxN/AEmployees7Year Founded2008Price Target and Rating Average Price Target for Aclarion$7.50 High Price Target$7.50 Low Price Target$7.50 Potential Upside/Downside+114.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($9.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.23 million Net Margins-10,320.51% Pretax Margin-10,321.80% Return on Equity-54.41% Return on Assets-51.71% Debt Debt-to-Equity RatioN/A Current Ratio19.65 Quick Ratio19.65 Sales & Book Value Annual Sales$77.88 thousand Price / Sales110.71 Cash FlowN/A Price / Cash FlowN/A Book Value$15.02 per share Price / Book0.23Miscellaneous Outstanding Shares2,462,000Free Float2,462,000Market Cap$8.62 million OptionableNot Optionable Beta1.22 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ACON) was last updated on 6/3/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
